CN116768804A — 一种(s)-2-(哌嗪-2-基)乙腈盐酸盐的制备方法
Assigned to Nanjing Youfu Pharmaceutical Technology Co ltd · Expires 2023-09-19 · 3y expired
What this patent protects
本发明属于医药中间体技术领域,具体涉及一种(S)‑2‑(哌嗪‑2‑基)乙腈盐酸盐的制备方法,该(S)‑2‑(哌嗪‑2‑基)乙腈盐酸盐的制备是以(R)‑1‑BOC‑3‑羟甲基哌嗪为起始原料,经过PMBCl保护、EsCl活化、TMSCN氰基化、ACE‑Cl脱PMB共四步反应得到成品。本发明提供的制备方法设计科学合理,制备过程中避免使用危险试剂、剧毒试剂和贵重试剂,能够以较低的成本来实现(S)‑2‑(哌嗪‑2‑基)乙腈盐酸盐的安全制备。
USPTO Abstract
本发明属于医药中间体技术领域,具体涉及一种(S)‑2‑(哌嗪‑2‑基)乙腈盐酸盐的制备方法,该(S)‑2‑(哌嗪‑2‑基)乙腈盐酸盐的制备是以(R)‑1‑BOC‑3‑羟甲基哌嗪为起始原料,经过PMBCl保护、EsCl活化、TMSCN氰基化、ACE‑Cl脱PMB共四步反应得到成品。本发明提供的制备方法设计科学合理,制备过程中避免使用危险试剂、剧毒试剂和贵重试剂,能够以较低的成本来实现(S)‑2‑(哌嗪‑2‑基)乙腈盐酸盐的安全制备。
Drugs covered by this patent
- Krazati (ADAGRASIB) · Bristol-Myers Squibb
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.